53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart and kidney failure in patients with type 2 diabetes, possibly due to diuretic effects. Previous non-placebo-controlled studies with SGLT2 inhibitors observed changes in volume markers in healthy individuals and in patients with type 2 diabetes with preserved kidney function. It is unclear whether patients with type 2 diabetes and signs of kidney damage show similar changes. Therefore, a post hoc analysis was performed on two randomized controlled trials ( n = 69), assessing effects of dapagliflozin 10 mg/day when added to renin–angiotensin system inhibition in patients with type 2 diabetes and urinary albumin-to-creatinine ratio ≥30 mg/g. Blood and 24-h urine was collected at the start and the end of treatment periods lasting six and 12 weeks. Effects of dapagliflozin compared to placebo on various markers of volume status were determined. Fractional lithium excretion, a marker of proximal tubular sodium reabsorption, was assessed in 33 patients. Dapagliflozin increased urinary glucose excretion by 217.2 mmol/24 h (95% confidence interval (CI): from 155.7 to 278.7, p < 0.01) and urinary osmolality by 60.4 mOsmol/kg (from 30.0 to 90.9, p < 0.01), compared to placebo. Fractional lithium excretion increased by 19.6% (from 6.7 to 34.2; p < 0.01), suggesting inhibition of sodium reabsorption in the proximal tubule. Renin and copeptin increased by 46.9% (from 21.6 to 77.4, p < 0.01) and 33.0% (from 23.9 to 42.7, p < 0.01), respectively. Free water clearance (FWC) decreased by −885.3 mL/24 h (from −1156.2 to −614.3, p < 0.01). These changes in markers of volume status suggest that dapagliflozin exerts both osmotic and natriuretic diuretic effects in patients with type 2 diabetes and kidney damage, as reflected by increased urinary osmolality and fractional lithium excretion. As a result, compensating mechanisms are activated to retain sodium and water.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

          To evaluate the effects of canagliflozin on plasma volume, urinary glucose excretion (UGE), fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and additional measures of fluid/electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects

            Background Dapagliflozin inhibits the sodium‐glucose–linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium‐glucose–linked transporter 2 inhibition causes an osmotic diuresis, we evaluated the diuretic interaction between dapagliflozin and bumetanide. Methods and Results Healthy subjects (n=42) receiving a fixed diet with ≈110 mmol·d−1 of Na+ were randomized to bumetanide (1 mg·d−1), dapagliflozin (10 mg·d−1), or both for 7 days, followed by 7 days of both. There were no meaningful pharmacokinetic interactions. Na+ excretion increased modestly with the first dose of dapagliflozin (22±6 mmol·d−1; P<0.005) but by more (P<0.005) with the first dose of bumetanide (74±7 mmol·d−1; P<0.005), which was not significantly different from both diuretics together (80±5 mmol·d−1; P<0.005). However, Na+ excretion with dapagliflozin was 190% greater (P<0.005) when added after 1 week of bumetanide (64±6 mmol·d−1), and Na+ excretion with bumetanide was 36% greater (P<0.005) when added after 1 week of dapagliflozin (101±8 mmol·d−1). Serum urate was increased 4% by bumetanide but reduced 40% by dapagliflozin or 20% by combined therapy (P<0.05). Conclusions First‐dose Na+ excretion with bumetanide and dapagliflozin is not additive, but the weekly administration of one diuretic enhances the initial Na+ excretion with the other, thereby demonstrating mutual adaptive natriuretic synergy. Combined therapy reverses bumetanide‐induced hyperuricemia. This requires further study in diabetic patients with hyperglycemia who have enhanced glycosuria and natriuresis with dapagliflozin. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00930865.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.

              Our aim was to investigate the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on urinary and serum glucose and electrolytes, urinary volume, osmolality, and the renin-angiotensin system in patients with type 2 diabetes.
                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                31 May 2019
                June 2019
                : 8
                : 6
                : 779
                Affiliations
                [1 ]Complications Research, Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark; mie.klessen.eickhoff@ 123456regionh.dk (M.K.E.); marie.frimodt-moeller@ 123456regionh.dk (M.F.-M.); peter.rossing@ 123456regionh.dk (P.R.); frederik.persson.01@ 123456regionh.dk (F.P.)
                [2 ]Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; c.c.j.dekkers@ 123456umcg.nl
                [3 ]Department of Nephrology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; b.j.kramers@ 123456umcg.nl (B.J.K.); r.t.gansevoort@ 123456umcg.nl (R.T.G.)
                [4 ]Department of internal medicine, Ziekenhuisgroep Twente, 7600 SZ Almelo, The Netherlands; g.laverman@ 123456zgt.nl
                [5 ]Department of Clinical Biochemistry, Rigshospitalet, 2100 Copenhagen Ø, Denmark; niklas.rye.joergensen@ 123456regionh.dk
                [6 ]Department of Endocrinology, Herlev & Gentofte Hospital, 2730 Herlev, Denmark; Jens.Faber@ 123456regionh.dk
                [7 ]Department of Internal Medicine, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands; a.danser@ 123456erasmusmc.nl
                [8 ]Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark
                Author notes
                [* ]Correspondence: h.j.lambers.heerspink@ 123456umcg.nl ; Tel.: +31-50-361-7859; Fax: +31-50-361-4087
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-5565-7240
                https://orcid.org/0000-0002-8486-1515
                https://orcid.org/0000-0003-3525-3772
                https://orcid.org/0000-0002-3126-3730
                Article
                jcm-08-00779
                10.3390/jcm8060779
                6616433
                31159350
                54ecd3ab-28ba-4be7-aa5a-950208d899f4
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 29 April 2019
                : 27 May 2019
                Categories
                Article

                sglt2 inhibitor,dapagliflozin,diabetic nephropathy,heart failure

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content843

                Cited by41

                Most referenced authors368